Thrombomodulin alfa - Asahi Kasei Pharma

Drug Profile

Thrombomodulin alfa - Asahi Kasei Pharma

Alternative Names: ART-123; AT 908; Human recombinant thrombomodulin - Asahi Kasei Pharma; Recombinant human soluble thrombomodulin - Asahi Kasei Pharma; Recombinant thrombomodulin alfa - Asahi Kasei Pharma; Recombinant thrombomodulin alpha - Asahi Kasei Pharma; Recomodulin; Recomodulin® anticoagulant intravenous infusion 12800; rhs-TM - Asahi Kasei Pharma; Thrombomodulin - Asahi Kasei v; Thrombomodulin alpha - Asahi Kasei Pharma; TMD-123

Latest Information Update: 19 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Asahi Kasei; Asahi Kasei Pharma Corp
  • Developer Asahi Kasei; Asahi Kasei Pharma America Corp; Asahi Kasei Pharma Corp
  • Class Anti-inflammatories; Anticoagulants; Antithrombotics; Peptides; Platelet membrane glycoproteins; Recombinant proteins
  • Mechanism of Action Protein C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Disseminated intravascular coagulation
  • Phase III Idiopathic pulmonary fibrosis
  • No development reported Deep vein thrombosis

Most Recent Events

  • 01 Jul 2016 Asahi Kasei Pharma Corporation initiates a phase I trial for prevention of treatment-related symptoms in postoperative Colon Cancer in Japan (NCT02792842)
  • 01 May 2016 Phase-III clinical trials in Idiopathic pulmonary fibrosis (In adults, In the elderly) in Japan (IV) (NCT02739165)
  • 13 May 2015 No recent reports on development identified - Phase-II for Disseminated intravascular coagulation in Malaysia and Thailand (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top